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Human breast cancers are broadly classified based on their gene-
expression profiles into luminal- and basal-type tumors. These two
major tumor subtypes express markers corresponding to the major
differentiation states of epithelial cells in the breast: luminal
(EpCAM+) and basal/myoepithelial (CD10+). However, there are also
rare types of breast cancers, such as metaplastic carcinomas, where
tumor cells exhibit features of alternate cell types that no longer
resemble breast epithelium. Until now, it has been difficult to iden-
tify the cell type(s) in the human breast that gives rise to these
various forms of breast cancer. Here we report that transformation
of EpCAM+ epithelial cells results in the formation of common forms
of human breast cancer, including estrogen receptor-positive and
estrogen receptor-negative tumors with luminal and basal-like
characteristics, respectively, whereas transformation of CD10+ cells
results in the development of rare metaplastic tumors reminiscent
of the claudin-low subtype. We also demonstrate the existence of
CD10+ breast cells with metaplastic traits that can give rise to skin
and epidermal tissues. Furthermore, we show that the develop-
ment of metaplastic breast cancer is attributable, in part, to the
transformation of these metaplastic breast epithelial cells. These
findings identify normal cellular precursors to humanbreast cancers
and reveal the existence of a population of cells with epidermal
progenitor activity within adult human breast tissues.
cell of origin | epidermal progenitor cells | luminal progenitors
Invasive breast cancer is a multifaceted disease consisting oftumors that exhibit a wide spectrum of histological and mo-
lecular features. Much attention has been focused on identifying
mutated or amplified genes in breast cancer to understand tumor
heterogeneity and develop targeted therapies. This work has
revealed that subclasses of breast tumors exhibit distinct con-
stellations of genetic aberrations and was the driving force be-
hind the development of targeted therapies for estrogen receptor
(ER)+ and HER2+ breast cancers. Despite these successes,
these findings fail to inform us about the details of how human
breast cancers begin, including the identity of the cellular origins
of breast cancer and how cell-intrinsic epigenetic programs in-
teract with genetic alterations to affect tumor phenotype.
Ductal carcinomas are the most common type of breast cancer,
accounting for ∼80% of all invasive tumors. They are broadly
categorized into two types, ER+ and ER− tumors, but can be
further subdivided molecularly and histologically into subclasses
with different prognostic outcomes and therapeutic sensitivities
(1). Molecular classification of tumors has shown that ER+ and
ER− tumors generally retain expression of markers of the two
major differentiation states of normal human breast tissue: lu-
minal and basal/myoepithelial (ME). ER+ tumors express hor-
mone receptors and genes characteristic of luminal epithelial
cells [e.g., cytokeratin (CK)8/18, CK19, CD24, Mucin 1 (MUC1),
GATA3, and epithelial cell adhesion molecule (EpCAM)]; in
contrast, ER− tumors lack estrogen-responsive genes and express
markers characteristic of basal/ME cells [e.g., α-smooth muscle
actin (αSMA), CD49f, p63, CK14, EGF receptor, and CD44].
ER− tumors also encompass rare cancers, such as medullary,
adenoid cystic, and metaplastic carcinomas, where the tumor
cells not only lack ER-responsive and luminal genes but also
exhibit features of alternate cell types not found in normal breast
epithelium (2, 3). Although ER− tumors exhibit a broad range of
characteristics, collectively they fall under the classification of
HER2+ and basal-like, including the recently identified claudin-
low subtype of breast cancers (2–4).
We have found that mutated tumor suppressors can act to dis-
rupt the differentiation programs of progenitor populations and
influence the type of tumor that will develop (5). However, studies
of blood cancers provide strong evidence that distinct lineage-
committed progenitors can give rise to different diseases (6, 7).
Moreover, in the case of solid tumors, the intrinsic differentiation
programs of cellular precursors were shown to contribute to the
heterogeneity and behavior of tumor cells (8, 9). It has been hy-
pothesized that ER+ luminal-type breast cancers may be derived
from luminal progenitor cells, whereas ER− basal-like breast can-
cers may be derived from basal/ME progenitor cells (10). However,
characterization of human breast luminal progenitor cells has
revealed overlapping gene- and surface marker-expression profiles
with basal-like tumors and cell lines (11, 12), suggesting that lu-
minal-lineage cells could be the source of basal-like breast cancers.
Thus, it remains unknown whether all human breast tumors are
derived from the same cellular precursors or whether different cell
types contribute to the heterogeneity of breast cancers. In this
study, we sought to examine the relationship between luminal and
basal/ME cells and breast cancer subtypes through use of the re-
cently described human-in-mouse (HIM) model (13, 14). With this
approach, we discovered unique properties of a cell population
within human mammary basal/ME epithelial cells that provide
important insights into the origins of rare breast cancers.
Results
Characterization of Breast Epithelial Cell Properties in Human Tissues.
Much recent effort has been focused on trying to define the hi-
erarchal relationships among epithelial cells in the breast. This
work has led to conflicting reports regarding the phenotype of
stem/progenitor cells and their relationship to differentiated
progeny (11, 15–18). EpCAM+MUC1− cells or EpCAM+CD49f+
cells were first reported to enrich for cells with bipotent potential
in human tissues (15, 16). In contrast, studies have also suggested
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that EpCAM−CD49f+ cells enrich for stem/progenitor compe-
tency (11, 17, 18). Because EpCAM and CD49f are also used to
identify populations of differentiated luminal and basal/ME cells
no unique set of cell surface markers can currently discriminate
progenitor cells from more mature cells. Given the ambiguities
surrounding the precise identity of progenitor cells, we chose to
evaluate mammary epithelial cells enriched within the two major
breast epithelial lineages to determine whether they might give
rise to distinct tumor subtypes.
Consistent with our previous reports (5, 12), flow cytometry
analysis of reduction mammoplasty tissues for EpCAM and
CD49f expression indicated that four populations of epithelial
cells could be identified: EpCAMhiCD49f−, EpCAMhiCD49f+,
EpCAMloCD49f+, and EpCAM−CD49f+ cells. We found that
CD10, a well-established marker of basal/ME cells was enriched
in the EpCAMloCD49f+ population, with an average of 74.4%
CD10+ cells in this fraction (P < 0.00035; Fig. 1A and Fig. S1 A
and B). In contrast, luminal populations with high expression
of EpCAM (EpCAMhiCD49f− and EpCAMhiCD49f+) showed
little CD10 expression (Fig. 1A and Fig. S1 A and B). Lineage
commitment of EpCAM/CD49f-expressing populations was pre-
viously confirmed (5, 12).
Based on these findings, we used an immunomagnetic strategy
to enrich for basal/ME-lineage cells (CD10+) and luminal-lineage
cells (EpCAM+CD10−, hereafter referred to as EpCAM+) (Fig.
1B and Fig. S1C). Flow cytometry analysis of EpCAM and CD49f
expression in sorted CD10+ cells and the fraction depleted of both
EpCAM+ and CD10+ cells confirmed that bead sorting for CD10
efficiently enriches for basal/ME EpCAMloCD49f+ cells, and
bead sorting for EpCAM efficiently recovers the EpCAMhi lu-
minal populations containing both CD49+ and CD49f− cells (Fig.
1C and Fig. S1D). Lineage was confirmed by immunofluorescence
on cytospun sorted CD10+ and EpCAM+ cells for markers of
luminal (CK8/18) and basal/ME cells (CK14) (Fig. S1E).
To further confirm that our sorting strategy enriches for
distinct populations of cells, we analyzed functional activities
in vitro by growing cells under adherent, nonadherent, and 3D
conditions. Unsorted primary human mammary epithelial cells
(HMECs) plated in serum-free mammary epithelial growth
medium (MEGM) formed colonies that grew in suspension as
well as distinct luminal, ME, and mixed adherent colonies that
could be distinguished morphologically and by expression of
CK14 and CK8/18 (Fig. 2A and Fig. S2 A and B). Under ad-
herent conditions, luminal EpCAM+ cells preferentially grew as
suspension colonies (P = 0.015). Rare colonies that did arise
from EpCAM+ cells were enriched for luminal-type CK8/18+
cells as well as two types of bipotent colonies: bipotent A,
composed of a central core of tightly arranged CK8/18+ cells
surrounded by CK14+ dispersed cells, and bipotent B, composed
of dispersed cells that contained mixed single- and double-pos-
itive cells (Fig. S2 A and B). In contrast, basal/ME lineage
CD10+ cells preferentially grew as adherent colonies, suggesting
that CD10+ cells represent the greatest contribution of cells that
expand in monolayer culture from unsorted HMECs under se-
rum-free conditions (P = 0.004; Fig. 2A and Fig. S2 A and B).



































































































Fig. 1. Enrichment of basal/ME and luminal populations from primary human
breast tissue. (A) Single-cell suspensions of humanbreast epithelial cells analyzed
by flow cytometry for expression of EpCAM, CD49f, and CD10 (n = 5 patient
samples). (Left) Representative dot plot of EpCAM and CD49f stained cells. Five
fractions of cells were gated and analyzed for CD10 content (%) as shown in the
histograms on the Right. (B) Schematic of immunomagnetic sorting strategy. (C)
Unsorted cells and fractions recovered after immunomagnetic sorting were an-
alyzed by flow cytometry for expression of EpCAM and CD49f (n = 3). Repre-
sentative dot plots from unsorted (patient 641), CD10+, and depleted cells are
shown. (Lower Right) Overlay of unsorted EpCAMhi, sorted CD10+, and depleted
fractions. Sorted EpCAM+CD10− cells did not stain with the fluorescently conju-
gated EpCAM antibody because of occupation of antigen sites from bead sort-
ing; however, the luminal EpCAMhi clouds from unsorted cells (red) are clearly
missing from the depleted fraction (blue). Enrichment of the EpCAMloCD49f+



























































































Fig. 2. EpCAM+CD10− luminal and CD10+ basal/ME sorted populations con-
tain cells with distinct functional characteristics. (A and B) Unsorted or sorted
fractions of cells were plated in adherent conditions (A) or nonadherent con-
ditions (B) and allowed to grow for 7–10d. Grapheddata represent average fold
± SE from independently sorted patient samples (n = 4–5). P values were
calculated by Student’s t test. (A Left) Representative image of suspension
colonies (arrows) and adherent colonies. (Bar: 200 μm.) (Right) Representative
images of crystal violet-stained colonies. (B) Immunofluorescence staining for
CK8/18 (red) and CK14 (green) in spheres formed in nonadherent conditions.
(Bar: 100 μm.) (C) Outgrowth from unsorted cells or sorted fractions plated on
collagen I gels. (Upper) Representative images of the three structures formed.
(Bar: 100 μm.) Graphed data represent average number ± SE from in-
dependently sorted patient samples (n = 3). P values were calculated by
Student’s t test. (D) Immunohistochemistry for luminal (CK19 and ERα) and
basal/ME (CK14 and αSMA) differentiation markers in bilayered structures
formed in vivo in the HIM model by sorted fractions. (Bar: 25 μm.)



















Notably, the majority of colonies derived from CD10+ cells were
bipotent B colonies and pure basal/ME colonies that stained
exclusively for CK14+ (Fig. S2 A and B).
Under nonadherent conditions, EpCAM+ cells also prefer-
entially grew in suspension compared with CD10+ cells, gener-
ating 6.8-fold more spheres that contained both CK8/18+ and
14+ cells (P = 0.0001; Fig. 2B and Fig. S2C). Spheres formed by
CD10+ basal/ME-lineage cells stained more predominantly for
CK14 and exhibited a compact morphology with a smooth outer
surface (Fig. 2B and Fig. S2 C and D). Although we cannot ex-
clude the possibility that aggregation in populations of EpCAM+
or CD10+ cells was responsible for colony formation under
nonadherent conditions, these results combined with adherent
colony-formation assays indicate that EpCAM+ and CD10+ cells
exhibit distinguishable biological activities in vitro.
Mammary morphogenesis assays (3D collagen I gel overlays)
were used to further assess EpCAM+ and CD10+ cells. In this
assay, unsorted primary HMECs formed three types of mor-
phologically distinct structures: flat monolayer colonies reminis-
cent of simple epithelium, round acinar colonies, and branching
ductal structures; the latter two are reminiscent of glandular
epithelium (Fig. 2C). Although there was considerable variation
in the capacity to form acinar structures among patient samples,
round acinar colonies were preferentially generated from cells
enriched in the EpCAM+ fraction (Fig. 2C). In contrast, cells
from the CD10+ fraction preferentially produced branching
ductal structures and flat colonies compared with EpCAM+ cells
(P = 0.0005 and P < 0.03, respectively; Fig. 2C).
Finally, sorted CD10+ and EpCAM+ cells were injected
in vivo to evaluate their outgrowth competency in the HIM
model (13, 14). Although EpCAM+ and CD10+ cells exhibited
differential activities in vitro, within the humanized cleared
fat-pad system, cells from both the CD10+ and EpCAM+ pop-
ulations could generate bilayered mammary outgrowths com-
prised of an inner luminal epithelial layer that expressed CK8/18
and CK19 and an outer epithelial layer that expressed CK14
(Fig. 2D, Fig. S3, and Table S1). Both fractions were also able to
generate differentiated mature luminal and ME cells, marked by
expression of ERα and αSMA (Fig. 2D and Fig. S3). Altogether,
these findings indicate that cells within the luminal and basal/ME
lineages exhibit distinguishing phenotypic and progenitor-like
functional activities and suggest that both lineages appear to
contain cells with bipotent differentiation capacity.
Creation of Luminal-Like, Basal-Like, and Metaplastic Human Breast
Cancers. To evaluate the influence of breast epithelial precursor
cells on tumor subtype, we modified the HIM model to create
human breast cancer tissues in vivo by introducing oncogenes
into freshly dissociated epithelial cells derived from reduction
mammoplasty tissues before injection into humanized mammary
fat pads. Importantly, the cells for these experiments were
maintained in vitro for no more than 18–24 h after dissociation
to avoid culture-adapted selection of cells.
Unsorted breast epithelial cells (n = 10 patient samples) were
transduced with lentiviruses harboring two different combina-
tions of transforming oncogenes (Fig. S4A): (i) mutant p53
(p53R175H), cyclin D1 (CCND1), myristoylated PI3K p110α
(PI3KCA), and mutant K-ras (RasG12V), hereafter termed
4onc; or (ii) SV40 early region (encoding large and small T
antigens) and mutant K-ras (RasG12V), hereafter termed SV40/
Ras. Tumor formation was observed with either oncogenic
combination across multiple patient samples (Table S2). Ex-
pression of the introduced genes was gauged by GFP expression,
immunostaining, and quantitative RT-PCR (qRT-PCR) (Fig. S4
B–E). Genomic fluorescence in situ hybridization showed that
the tumor cells were not of mouse origin, confirming derivation
from human cells (Fig. S4F). Microscopic and immunohisto-










































































































































































Fig. 3. Tumors formed from sorted fractions have distinct phenotypes. (A) Representative images from tumors derived from unsorted and sorted fractions
transformed with the SV40/Ras oncogene combination stained for ERα, CK14 and CK8/18, and CK19. (Bars: 200 μm.) (B) Quantification of CK14 and CK19
expression (n = 8–9 tumors per group; immunofluorescence) and ERα expression (n = 4–7 tumors per group; immunohistochemistry) across tumors from 4onc
and SV40/Ras models. Graphs represent average ± SE. P values were calculated by one-way ANOVA (CK19 and CK14) or Student’s t test (ERα). (C) Heat map of
hierarchical clustering of global gene-expression data collected from SV40/Ras tumors (n = 20) arising from unsorted (blue) or sorted CD10+ (green), EpCAM+
(red), EpCAM+/CD49f+ (yellow), or EpCAM+/CD49f− (magenta) cells. (D) Differentiation status of the various SV40/Ras tumors along a normal breast de-
velopment axis using the Genomic Differentiation Predictor described in ref. 4. The P value was calculated by comparing gene-expression means across
unsorted and sorted tumor groups. (E) Enrichment of the CD10 Signature derived from CD10+ tumors across a panel of breast tumor intrinsic subtypes from
the UNC337 data set (Gene Expression Omnibus accession no. GSE18229). P value was calculated by comparing gene-expression means across all subtypes.
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cells were heterogeneous carcinomas with features of luminal,
basal, and even rare squamous/metaplastic differentiation irre-
spective of the patient samples or oncogene model from which
they were derived (Fig. 3A and Fig. S5 A–C). Immunostaining
demonstrated that cancer cells in squamous regions expressed
CK14, indicative of basal differentiation, and those within pap-
illary/glandular regions expressed CK8/18, indicative of luminal
differentiation (Fig. S5B).
The finding that breast tumors from unsorted cells exhibited
a mixed phenotype, containing both luminal and basal features,
suggested the possibility that these tumors were derived from
a mixture of transformed basal/ME- and luminal-lineage epi-
thelial cells. To address whether transformation of luminal and
basal/ME cells led to the formation of tumors with luminal and
basal/ME-like features, respectively, epithelial cells from re-
duction mammoplasty tissues were sorted for EpCAM+ and
CD10+ cells before oncogenic transduction as previously de-
scribed (5). Examination of unsorted and sorted cells after in-
fection in either 4onc or SV40/Ras models revealed similar gene-
transduction efficiencies (Fig. S4 B–E).
Transformation of luminal EpCAM+ cells (n = 7 patient
samples) with either combination of transforming oncogenes led
primarily to the formation of ductal carcinomas with predominant
luminal features, including expression of ERα, CK8/18, and CK19
(Fig. 3 A and B and Fig. S5C). Because EpCAM+ cells enrich
for heterogeneous populations of luminal epithelial cells based
on CD49f expression (11, 12, 16–18), we further sorted the
EpCAM+ fraction into CD49f+ or CD49f− cells before lentiviral
transduction (Fig. S6A). Interestingly, transformation of CD49f−
luminal cells with SV40/Ras resulted in the development of
tumors with significantly higher expression of ERα and reduced
expression of basal CK14 compared with CD49f+ tumors (Fig. S6
B and C). In contrast to EpCAM+ tumors, tumors derived from
CD10+ cells (n = 7 patient samples) exhibited pronounced
squamous, metaplastic, and giant cell differentiation concomitant
with a marked lack of ERα expression (P = 0.006; Fig. 3 A and B
and Fig. S5C), significant decrease in luminal CK expression
(CK19; P = 0.001), and robust expression of the basal marker
CK14 (P = 0.0006) (Fig. 3 A and B and Fig. S5C).
To more comprehensively define the phenotype of the tumors
generated, we performed global gene-expression analyses on
RNA isolated from tumors arising from unsorted, EpCAM+, or
CD10+ cells as well as from tumors derived from EpCAM+/
CD49f+ and EpCAM+/CD49f− cells. Unsupervised hierarchical-
clustering analysis indicated that tumors arising from EpCAM+
or CD10+ cells could be segregated from one another (Fig. 3C
and Dataset S1). Interestingly, tumors derived from unsorted
cells clustered more closely with tumors arising from CD10+
cells than with those derived from EpCAM+ cells. In addition,
although tumors derived from EpCAM+/CD49f+ and EpCAM+/
CD49f− cells could be distinguished from unsorted or CD10+
sorted cells, they could not be distinguished from tumors derived
from bulk EpCAM+ cells (Fig. 3C and Dataset S1).
Gene set enrichment analysis (GSEA) showed significant
enrichment of genes derived from pairwise comparisons of
EpCAM+ and CD10+/unsorted tumors with genes associated
with luminal, basal, and stem cell differentiation (Datasets S1,
S2, and S3). Consistent with GSEA, when tumor differentiation
was analyzed with the recently described Genomic Differentia-
tion Predictor (4), tumors derived from EpCAM+ cells were
more differentiated compared with CD10+ and unsorted-derived
tumors (P = 0.0286; Fig. 3D).
We derived a “CD10 Signature” based on the genes that were
differentially expressed between tumors derived from CD10+
sorted cells compared with tumors derived from all EpCAM+
cells (including EpCAM+/CD49f+ and EpCAM+/CD49f− cells;
Dataset S4) and then examined this signature across the intrinsic
















































































































































Fig. 4. vCD10+ cells spontaneously lose mammary fate specification and gain ability to form skin tissues. (A) Representative graph of long-term culture of
sorted CD10+ and EpCAM+ cells grown in MEGM showing the formation of vHMEC cells (vCD10+) preferentially from sorted CD10+ cells (n = 5 independently
sorted patient samples). (B) Summary of mammary fate gene expression as analyzed by custom qRT-PCR array in P1 CD10+ compared with vCD10+ cells (n = 3
from independently sorted patient samples). (C) Outgrowth from P1 CD10+, vCD10+, MCF10A, and HaCAT cells plated on collagen I gels. (D) Representative
images of sections from HSE assays stained for H&E, CK1/10, involucrin, E-cadherin, and laminin V (n = 3 from independently sorted or immortalized patient
samples for each condition). (Bars: 100 μm.) (Inset) An example of ductal-like growths into the collagen gels from P1 CD10+ cells is shown. (E) Heat map of
hierarchical clustering of global gene-expression data collected from a panel of HMECs: primary vHMECs (vHMEC-1, vHMEC-2, and vHMEC-3) isolated from three
patients, immortalized HMECs (HME-CC and ME16C), and MCF10A, MCF12F, and MCF12A cells. Comparison with the CD10 Signature is shown on the right.



















estingly, the CD10 Signature was most enriched in claudin-low
tumors (P =1.98 × 10−22; Fig. 3 E), which are associated with
metaplastic, mesenchymal, and mammary stem cell-like charac-
teristics (4, 19). Concordant with this finding, the CD10 Signa-
ture was also enriched in published gene-expression data from
the mammary stem cell population (11) (P = 1.98 × 10−6; Fig.
S7). Altogether, these results suggest that EpCAM+ epithelial
cells serve as precursors for differentiated ER+ and ER− ductal
carcinomas, whereas CD10+ cells serve as precursors for rare
and undifferentiated metaplastic/claudin-low carcinomas.
Cells with Metaplastic Potential Reside Within Adult Human CD10+
Breast Epithelium. Because transformation of CD10+ cells resul-
ted in the formation of metaplastic breast cancers, we reasoned
that breast epithelial cells within the CD10+ population might
contain cells with metaplastic potential, i.e., reduced mammary
specification, before neoplastic transformation. Ex vivo cultivation
of HMECs selects for variant cells that exhibit significant differ-
ences in gene-expression profiles, lineage markers, and chromatin
methylation states compared with primary HMECs (20, 21). We
reasoned that these cells might be enriched within the CD10+
lineage and may exhibit features of alternate cell types. Indeed, we
readily observed the emergence of variant HMEC (vHMEC) cells
from cultured CD10+ cells (n= 5 patients); in contrast, EpCAM+
cells rarely gave rise to variant cells (Fig. 4A and Fig. S8 A and B).
To determine whether these variant cells exhibited metaplastic
features, short-term cultures of CD10+ cells harvested at the first
passage (P1 CD10+ cells) as well as variant CD10+ cells har-
vested during exponential growth after escape from stasis/selec-
tion (vCD10+ cells) were examined for the expression of 84
genes associated with mammary differentiation by qRT-PCR
(Table S3). Consistent with previous reports (20), P1 CD10+
cells expressed a range of ME, luminal, and progenitor lineage
markers (αSMA, CK19, oxytocin receptor, progesterone re-
ceptor, CK8, and myosin light chain kinase), whereas vCD10+
lacked expression of many genes associated with mammary dif-
ferentiation (Fig. 4B and Table S3).
Because the mammary gland is an epidermal appendage and
metaplastic tumors are associated with features of epidermal
differentiation, including squamous and apocrine differentiation,
we reasoned that vCD10+ cells might exhibit features of epi-
dermal cells. To investigate, we first assessed the morphogenesis
competency of P1 CD10+, vCD10+, and vHMEC cells in collagen
I gel overlay assays. HaCAT human epidermal-derived keratino-
cyte cells used as an epidermal control predominantly formed
round structures in contrast to round and branching ductal struc-
tures formed by the MCF10A mammary cell line. In comparison to
P1 CD10+ cells, vCD10+ cells produced significantly fewer
branching ductal colonies and exhibited an increase in flat and
round colony formation (Fig. 4C and Fig. S9A).
We next assessed whether vCD10+ or vHMEC cells had the
ability to form epidermal tissues. P1 CD10+ cells, vCD10+ cells,
and vHMECs were seeded onto collagen matrix containing adult
human dermal fibroblasts and grown in a human skin equivalents
(HSE) assay. In this assay, HaCAT cells formed stratified epider-
mal tissues displaying basal, spinous/granular, and cornified layers
as well as expression of E-cadherin at cell junctions, localization of
involucrin and CK1/10 to the spinous/granular layers, and laminin
V deposition on the basement membrane (Fig. S9B). Remarkably,
vCD10+ cells and immortalized vHMECs were able to form skin-
like tissues in 3D HSE cultures that also displayed stratified layers
and expression of skin markers (Fig. 4D and Fig. S9B). In contrast,
P1 CD10+ cells formed ductal invaginations into the collagen
matrix, reminiscent of rudimentary mammary structures, and did
not stain for involucrin or CK1/10.MCF10A cells were not capable
of forming stratified epidermal tissue, indicating that formation of
skin tissues is not a property of all cultured HMECs (Fig. S9C).
In addition to epidermal differentiation capacity, gene-ex-
pression analysis of primary vHMECs (n = 3 patient samples),
two immortalized vHMEC lines, and the MCF10A, MCF12F,
and MCF12A cell lines revealed that vHMECs and immortalized
vHMECs, but not MCF10A, MCF12F, and MCF12A cells,
are enriched in the metaplastic CD10 Signature (Fig. 4E and
Fig. S9D). Collectively, these results imply that cells within the
CD10+ breast epithelial lineage have the capacity to exhibit
metaplastic features before neoplastic transformation.
Creation of Metaplastic Tumors from HMECs. To determine whether
metaplastic breast epithelial cells were indeed precursors to
metaplastic breast cancer, immortalized vHMECs were trans-
formed with the SV40/Ras oncogenes as previously described
(22), and tumors were examined by histopathological analysis.
Consistent with previous reports (22), transformed vHMECs
formed tumors that exhibited mixed epidermal and metaplastic
features including squamous, spindle-cell, medullary, and giant
cell differentiation (Fig. 5A and Fig. S10 A and B). Interestingly,
transduced vHMECs that were unable to form expansive tumors
created tissues that resembled human sebaceous glands, albeit
somewhat disorganized, consistent with dedifferentiation into an
early epidermal state (Fig. 5A and Fig. S10A). Concordant with
these findings, we observed a significant enrichment of the CD10
Signature in a panel of human metaplastic, adenoid cystic, and
medullary carcinomas from a microarray dataset of special his-
tological breast cancer types (23) and remarkable similarity to
histopathology of human metaplastic breast cancers (Fig. 5B and
Fig. S10C). Given the histological and molecular similarities
between tumors derived from CD10+ cells and vHMECs, these
results strongly support the notion that the cellular precursors to
rare metaplastic breast carcinomas may reside within the CD10+
cell population.
































































Fig. 5. Transformed vHMEC cells give rise to metaplastic tumors. (A) Im-
mortalized vHMECs from unsorted cells give rise to disorganized sebaceous-
like growths (Upper Left) as well as tumors with medullary (Upper Right),
spindle/giant-cell (Lower Left; arrows indicate giant cells), and squamous
(Lower Right) histologies when transformed with SV40/Ras. (Bars: 100 μm.)
(B) Enrichment of the CD10 Signature, derived from CD10+ tumors, across
a panel of 11 special histological types of breast cancer from ref. 23.
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Discussion
The enumeration of the cellular and functional activities of
various cell types within human and mouse mammary tissues has
been an area of intense investigation for understanding the cel-
lular origins of breast cancers (10). Although breast stem/pro-
genitor cells have been localized to cells within both main and
terminal ducts (16), the precise identity of human mammary
stem cells is an area of contentious debate and remains ill de-
fined. Some studies claim that stem/progenitor cells in human
breast tissues reside within the luminal EpCAM+/MUC1− or
EpCAM+/CD49f+ population (15, 16), whereas other reports
claim they reside within the basal/ME EpCAM−/CD49f+ pop-
ulation (11, 17, 18). Through in vivo and in vitro characterization
of cells from EpCAM+ luminal and CD10+ basal/ME lineages,
we found important functional distinctions between these two
lineages and also that both populations retain some functional
progenitor competency, which may explain why stem/progenitor
activity has been difficult to exclusively measure from a unique
and distinctive population of breast epithelial cells.
Through use of the HIM tumor model, we have also been able
to address one of the major questions regarding human breast
tumor heterogeneity, namely, how different pools of progenitor
cells in normal human breast tissue contribute to tumor pheno-
type. Our results strongly imply that the great majority of human
breast cancers are likely derived from EpCAM+ luminal epi-
thelial cells because EpCAM+ cells were able to give rise to both
ER+ and ER− tumors, indicating that basal-like tumors need not
originate from basal/ME progenitor cells. This finding is in
agreement with the previously speculated but untested hypothesis
that human basal-like breast cancers may arise from luminal
progenitor cells and the observation that most basal-like tumors
lack CD10 expression (5, 11, 12, 24). Our data from the trans-
formation of EpCAM+/CD49f− cells also supports the hypothesis
that tumors can be derived from a pool of more mature luminal
cells, as has been speculated based on similarities between gene-
expression profiles of human luminal tumors and the differenti-
ated luminal cell fraction of human breast tissue (11). Finally, our
data indicate that basal/ME CD10+ cells are likely the source of
rare types of breast tumors such as metaplastic tumors.
Although we have demonstrated that EpCAM+/CD49f− cells
can serve as precursors to ER+ breast cancers, gene-expression
analysis was unable to distinguish these tumors from those de-
rived from EpCAM+/CD49f+ cells, suggesting that ER+ tumors
could be derived from the same common luminal progenitor cell
as ER− tumors and/or that the oncogenes used to transform
EpCAM+/CD49f− cells affected their differentiation potential.
Consistent with these notions are the recent findings that mu-
tations in BRCA1 can affect the differentiation potential of
luminal progenitor cells, leading to increased basal-like differ-
entiation in tumors (5, 11). Because carcinoma cells from lumi-
nal ER+ and basal-like ER− breast cancers are reported to
contain distinguishing and even mutually exclusive sets of mu-
tated or misregulated genes (25), the genetic and epigenetic
alterations sustained during early stages of transformation could
alter differentiation commitment programs in a common cell of
origin, leading to tumors with different phenotypes. In this
model, undifferentiated tumors could result when the common
cell of origin lost lineage commitment potential during the ac-
quisition of malignancy. Additional studies will be needed with
alternative combinations of transforming oncogenes to fully sep-
arate the contribution of the cell of origin from the role gene
mutation has on differentiation programs and tumor phenotype.
In addition, further studies that separate subpopulations of
CD10+ cells and substitute other combinations of transforming
oncogenes will be necessary to fully elucidate the contribution
CD10+ cells on the development of other types of breast cancers.
Materials and Methods
Immunomagnetic bead sorting was used to isolate luminal and basal/ME
populations from reduction mammoplasty tissue. Tumors were generated by
lentiviral introduction of oncogenes and were characterized by protein and
gene expression. All methods describing primary tissue isolation, flow
cytometry, animal surgeries, in vitro assays, and gene-expression analysis are
included in SI Materials and Methods.
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